COPENHAGEN (Reuters) -Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its weight-loss drug candidate petrelintide in people with overweight or obesity.
Petrelintide belongs to a class of drugs known as the long-acting amylin analog, which mimics a hormone called amylin that is co-secreted with insulin in response to ingested nutrients.
The company expects to initiate its mid-stage trial of petrelintide in people with overweight or obesity with type 2 diabetes in the first half of 2025, it said in a statement.
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)
Comments